In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011

Executive Summary

Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.

Advertisement

Related Content

Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing
IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Rib-X Counting On Rational Drug Design To Outsmart Resistant Bacteria
Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure
Merck Out-Licenses Gene Therapy Assets To FKD Therapies
Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011
Danone Buys Wockhardt's Nutrition Brands That Abbott Won Then Lost
Acceleron And Celgene Expand Anemia Collaboration With Second Compound
Express Scripts-Medco Deal Fits Post-Health Reform Realities, But Was Hastened By Contract Losses

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel